Hepatitis b vaccine (recombinant), adjuvanted - Biologic Drug Details

Summary for hepatitis b vaccine (recombinant), adjuvanted

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for hepatitis b vaccine (recombinant), adjuvanted

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Hepatitis B Virus Vaccine
Chemical Structure	Hepatitis B Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for hepatitis b vaccine (recombinant), adjuvanted Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for hepatitis b vaccine (recombinant), adjuvanted Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Dynavax Technologies Corporation	HEPLISAV-B	hepatitis b vaccine (recombinant), adjuvanted	Injection	125428	10,314,907	2038-01-18	DrugPatentWatch analysis and company disclosures
Dynavax Technologies Corporation	HEPLISAV-B	hepatitis b vaccine (recombinant), adjuvanted	Injection	125428	9,452,212	2032-04-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for hepatitis b vaccine (recombinant), adjuvanted Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

Market Dynamics and Financial Trajectory for the Biologic Drug: Hepatitis B Vaccine (Recombinant), Adjuvanted

Last updated: July 28, 2025

Introduction

The global hepatitis B vaccine market is a crucial segment within the broader infectious disease vaccine landscape, driven by increasing vaccination rates, emerging market adoption, and the evolving landscape of immunization strategies. The recombinant, adjuvanted hepatitis B vaccine (HBV) signifies technological advancements aimed at enhancing immunogenicity, dosage compliance, and long-term immunity. Analyzing the market dynamics and projecting the financial trajectory requires an understanding of epidemiological trends, regulatory environments, competitive landscape, and technological innovations.

Epidemiological and Market Drivers

Global Hepatitis B Burden

Hepatitis B remains a significant health concern worldwide, with an estimated 296 million chronic carriers globally as of 2019, according to WHO [1]. Chronic HBV infection predisposes individuals to cirrhosis, hepatocellular carcinoma, and liver failure. The high disease burden fuels vaccination initiatives, especially in high-endemic regions such as Africa, Southeast Asia, and parts of the Eastern Mediterranean.

Vaccination Policies and Coverage

Universal vaccination policies, particularly involving recombinant vaccines, have markedly reduced HBV transmission in countries like the United States, China, and several European nations. WHO recommends administering a three-dose series at birth, one of the main strategies to prevent mother-to-child transmission [2]. The increase in childhood immunization coverage enhances demand for advanced vaccines, including adjuvanted recombinant formulations.

Technological Evolution and Adjuvants

Initial recombinant hepatitis B vaccines employed alum-based adjuvants. Recent advancements have introduced novel adjuvants—like Toll-like receptor (TLR) agonists—improving immunogenicity, especially in populations with impaired immune responses (e.g., neonates, immunocompromised) [3]. Enhanced efficacy attracts interest from manufacturers aiming to improve compliance and long-term protection.

Market Consolidation and Competitive Dynamics

The market features key players like GSK, Merck, and Bharat Biotech, with emerging entrants bringing biosimilar or improved adjuvanted vaccines. Strategic collaborations and licensing agreements are common, expanding geographic reach and manufacturing capacity.

Market Segmentation and Regional Outlook

By Product Type

• Recombinant, Alum-Adjuvanted Vaccines: Dominant worldwide due to proven safety and effectiveness.

• Recombinant, Adjuvanted Vaccines: Growing niche, focusing on enhanced immunogenicity and shorter dosing schedules.

Regional Market Trends

• North America & Europe: Mature markets with high vaccination coverage; innovation-driven with increased adoption of adjuvanted vaccines aimed at booster doses and special populations.

• Asia-Pacific: The fastest-growing region, driven by high endemicity, government initiatives, and expanding immunization programs. China’s recent approval of adjuvanted formulations reflects this trend.

• Africa & Middle East: Increasing acceptance, partly driven by WHO mandates, but constrained by logistical and infrastructure challenges.

Market Challenges and Opportunities

Challenges

• Pricing and Reimbursement: Pricing pressures from governments and insurers challenge profitability, especially in emerging markets.

• Regulatory Hurdles: Varied approval pathways and regulatory rigor in different regions can delay product launches.

• Vaccine Hesitancy: Misinformation and skepticism toward vaccines reduce uptake, affecting growth potential.

Opportunities

• Innovative Adjuvants: Continued R&D into adjuvants can offer higher efficacy, reduced dosing, and improved long-term immunity.

• Combination Vaccines: Development of combination vaccines (e.g., HBV with hepatitis A) offers added convenience and market appeal.

• Expanding Indications: Trials exploring hepatitis B vaccines for post-exposure prophylaxis and therapeutic contexts could open new markets.

Financial Trajectory and Forecasting

Historical Market Performance

The hepatitis B vaccine market was valued at approximately USD 2.8 billion in 2021, with a compound annual growth rate (CAGR) of around 5.5% from 2016 to 2021 [4]. The growth was primarily driven by increased coverage in emerging markets and technological innovations.

Projected Market Growth

Forecasts indicate the market could reach USD 4.2 billion by 2030, representing a CAGR of approximately 6% throughout the decade. The accelerated growth rate reflects:

• Increasing integration of adjuvanted recombinant vaccines, especially with novel adjuvants.
• Expansion into adult vaccination, including high-risk populations.
• Post-pandemic focus on infectious disease preparedness boosting vaccine demand.

Factors Influencing Financial Outcomes

• Product Innovation: Companies investing in adjuvant research are poised for premium pricing and market differentiation.
• Regulatory Support: Emergency use authorizations and streamlined approval pathways can accelerate product access.
• Market Penetration: Regional expansion, especially in high-bredicate countries, translates into revenue growth.
• R&Doutsourcing: Contract manufacturing and collaborations reduce costs and accelerate commercialization timelines.

Key Market Players and Strategic Moves

• GSK: Notably advanced in adjuvanted formulations, leveraging proprietary adjuvant systems.
• Merck (MSD): Focus tools on recurring immunization schedules, with ongoing trials in booster formulations.
• Bharat Biotech: Expanding presence in Asia with affordable, adjuvanted recombinant vaccines.
• Other regional manufacturers are investing in adjuvant technology to differentiate their offerings and capture emerging markets.

Regulatory Landscape

Global approvals hinge on safety, efficacy, and manufacturing standards. The US FDA, EMA, and WHO prequalification provide pathways for broader acceptance. Recent regulatory encouragement for simplified approval processes in low- and middle-income countries further supports market expansion.

Technological and Market Trends

• Adoption of adjuvants like AS04 enhances potency and immunogenicity [3].
• Development of heat-stable formulations addresses cold chain challenges, expanding access.
• Increasing public-private partnerships promote vaccine deployment in underserved regions.

Conclusion

The market for recombinant, adjuvanted hepatitis B vaccines sits at the intersection of technological innovation, public health imperatives, and evolving regulatory landscapes. The anticipated robust growth reflects both ongoing global efforts to eliminate hepatitis B and continuous advancements in vaccine technology. Stakeholders must prioritize R&D in adjuvant systems, navigate regional nuances, and align with public health policies to capitalize on emerging opportunities.

---

Key Takeaways

• The hepatitis B vaccine market, valued at approximately USD 2.8 billion in 2021, is projected to grow at about 6% annually through 2030.
• Advances in adjuvant technology underpin market expansion, offering improved immunogenicity, shorter schedules, and better efficacy in vulnerable populations.
• Emerging markets in Asia and Africa present significant growth opportunities, driven by high endemicity and expanding immunization programs.
• Regulatory pathways and pricing strategies remain critical for successful market penetration.
• Innovation in heat-stable formulations and combination vaccines will further elevate market dynamics.

---

FAQs

1. How does adjuvant technology enhance hepatitis B vaccines?
Adjuvants amplify the immune response, enabling lower antigen doses, reducing dosing schedules, and improving long-term immunity, particularly beneficial for neonates and immunocompromised individuals.

2. What regions hold the most growth potential for recombinant adjuvanted hepatitis B vaccines?
Asia-Pacific and Africa are key regions due to high endemicity, expanding immunization initiatives, and increasing healthcare infrastructure.

3. What are the main challenges facing market expansion?
Pricing, regulatory approvals, vaccine hesitancy, and logistical barriers like cold chain maintenance hinder growth, especially in low-resource settings.

4. Are there any upcoming technological innovations in hepatitis B vaccines?
Yes. Novel adjuvants, thermostable formulations, and combination vaccines are under development, aiming to improve efficacy, compliance, and access.

5. How can manufacturers capitalize on the future market trajectory?
Investing in innovative adjuvant research, forging strategic partnerships, streamlining regulatory approval processes, and tailoring products for emerging markets are key strategies.

---

Sources:

[1] World Health Organization. (2021). Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
[2] WHO. (2017). Hepatitis B vaccines: WHO position paper. Weekly Epidemiological Record, 92(27), 369–392.
[3] Didierlaurent, A., et al. (2018). Adjuvants and immune response: innovations in hepatitis B vaccination. Vaccine, 36(44), 6598–6604.
[4] Market Research Future. (2022). Hepatitis B vaccine market analysis.